纽约心功能分级与患者报告结局在射血分数降低心衰中的比较
该队列研究纳入2872例美国慢性射血分数降低心衰门诊患者,比较NYHA分级与KCCQ-OS的纵向变化及与临床结局的关联。12个月内KCCQ-OS变化更敏感,KCCQ-OS改善≥5分独立关联死亡率降低(HR 0.59),而NYHA改善与后续结局无关。
要点
- KCCQ-OS对心衰患者健康状态变化比NYHA分级更敏感。
- KCCQ-OS改善≥5分独立关联死亡和心衰住院风险降低。
- NYHA分级改善与后续临床结局无独立关联。
核心结论
- 在当代美国临床实践中,KCCQ-OS比NYHA分级对健康状态的有意义变化更敏感。
- KCCQ-OS变化可能比NYHA分级变化具有更大的预后价值。
研究设计与样本
- 队列研究,纳入2872例美国慢性射血分数降低心衰门诊患者,来自145家中心,2015年12月至2017年10月入组CHAMP-HF注册。
- 所有患者基线和12个月均有完整NYHA分级和KCCQ-OS数据。
- 多变量模型以12个月为界标,评估基線至12个月NYHA和KCCQ-OS改善与12至24个月临床结局的关联。
主要发现
- 基线NYHA I、II、III、IV级分别为312例(10.9%)、1710例(59.5%)、804例(28.0%)、46例(1.6%)。
- 基线KCCQ-OS 75-100、50-74、25-49、0-24分分别为1131例(39.4%)、967例(33.7%)、612例(21.3%)、162例(5.6%)。
- 12个月时1002例(34.9%)NYHA分级变化(599例[20.9%]改善,403例[14.0%]恶化),2158例(75.1%)KCCQ-OS变化≥5分(1388例[48.3%]改善,770例[26.8%]恶化)。
- NYHA最常见轨迹为无变化(1870例[65.1%]),KCCQ-OS最常见轨迹为改善≥10分(1047例[36.5%])。
- 校正后NYHA改善与后续临床结局无关,KCCQ-OS改善≥5分独立关联死亡率降低(HR 0.59;95%CI 0.44-0.80;P<.001)和死亡或心衰住院降低(HR 0.73;95%CI 0.59-0.89;P=.002)。
临床怎么用
- 在心衰门诊随访中可优先使用KCCQ-OS评估健康状态变化。
- KCCQ-OS改善≥5分提示预后改善,应关注并强化治疗。
- NYHA分级变化不宜单独作为预后判断依据。
局限性
- 研究为观察性队列,无法确立因果关系。
- 仅纳入基线和12个月数据完整的患者,可能存在选择偏倚。
- 人群以白人为主(75.1%),外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is unclear how New York Heart Association (NYHA) functional class compares with patient-reported outcomes among patients with heart failure (HF) in contemporary US clinical practice. OBJECTIVE: To characterize longitudinal changes and concordance between NYHA class and the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS), and their associations with clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included 2872 US outpatients with chronic HF with reduced ejection fraction across 145 practices enrolled in the CHAMP-HF registry between December 2015 and October 2017. All patients had complete NYHA class and KCCQ-OS data at baseline and 12 months. Longitudinal changes and correlations between the 2 measure were examined. Multivariable models landmarked at 12 months evaluated associations between improvement in NYHA and KCCQ-OS from baseline to 12 months with clinical outcomes occurring from months 12 through 24. Statistical analyses were performed from March to August 2020. EXPOSURE: Change in health status, as defined by 12-month change in NYHA class or KCCQ-OS. MAIN OUTCOMES AND MEASURES: All-cause mortality, HF hospitalization, and mortality or HF hospitalization. RESULTS: In total, 2872 patients were included in this analysis (median [interquartile range] age, 68 [59-75] years; 872 [30.4%] were women; and 2156 [75.1%] were of White race). At baseline, 312 patients (10.9%) were NYHA class I, 1710 patients (59.5%) were class II, 804 patients (28.0%) were class III, and 46 patients (1.6%) were class IV. For KCCQ-OS, 1131 patients (39.4%) scored 75 to 100 (best health status), 967 patients (33.7%) scored 50 to 74, 612 patients (21.3%) scored 25 to 49, and 162 patients (5.6%) scored 0 to 24 (worst health status). At 12 months, 1002 patients (34.9%) had a change in NYHA class (599 [20.9%] with improvement; 403 [14.0%] with worsening) and 2158 patients (75.1%) had a change of 5 or more points in KCCQ-OS (1388 [48.3%] with improvement; 770 [26.8%] with worsening). The most common trajectory for NYHA class was no change (1870 [65.1%]), and the most common trajectory for KCCQ-OS was an improvement of at least 10 points (1047 [36.5%]). After adjustment, improvement in NYHA class was not associated with subsequent clinical outcomes, whereas an improvement of 5 or more points in KCCQ-OS was independently associated with decreased mortality (hazard ratio, 0.59; 95% CI, 0.44-0.80; P < .001) and mortality or HF hospitalization (hazard ratio, 0.73; 95% CI, 0.59-0.89; P = .002). CONCLUSIONS AND RELEVANCE: Findings of this cohort study suggest that, in contemporary US clinical practice, compared with NYHA class, KCCQ-OS is more sensitive to clinically meaningful changes in health status over time. Changes in KCCQ-OS may have more prognostic value than changes in NYHA class.
引用
- Greene SJ, Butler J, Spertus JA, et al. Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2021. PMID: 33760037. doi:10.1001/jamacardio.2021.0372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。